Avastin Bid For Full Approval In Metastatic Breast Cancer May Require Another Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Roche/Genentech's follow-up studies did not produce clinically meaningful results using the progression-free survival endpoint.
You may also be interested in...
Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics
The Oncology Drugs Advisory Committee's vote against full approval of Roche's Avastin (bevacizumab) for first-line treatment of metastatic breast cancer hinged to a large degree on its feeling that the drug did not delay disease progression long enough to be clinically meaningful
Avastin Breast Cancer Approval Debate Pits Clinical Benefit Versus Statistics
The Oncology Drugs Advisory Committee's vote against full approval of Roche's Avastin (bevacizumab) for first-line treatment of metastatic breast cancer hinged to a large degree on its feeling that the drug did not delay disease progression long enough to be clinically meaningful
Avastin's Last Hope For Breast Cancer Claim May Be Subpopulations
FDA advisory committee votes to remove the breast cancer treatment indication from the Genentech drug's label after failed confirmatory trial, but two more studies are on their way.